Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia (SOLITAIRE-IV)
A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in the Treatment of Adult Patients With Community-Acquired Bacterial Pneumonia
Sponsor: Melinta Therapeutics, Inc.
A PHASE3 clinical study on Community-acquired Bacterial Pneumonia, this trial is completed. The trial is conducted by Melinta Therapeutics, Inc. and has accumulated 11 data snapshots since 2013. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
11 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Nov 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2025 — Nov 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE3
-
May 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — May 2019 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Nov 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Melinta Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Akron, United States , Alicante, Spain , Alor Star, Malaysia , Ampang, Malaysia , Ansan-si, South Korea , Anyang-si, South Korea , Augusta, United States , Badalona, Spain , Balvi, Latvia , Barcelona, Spain and 200 more locations